Royalty Pharma (RPRX) Cash from Financing Activities (2019 - 2026)

Royalty Pharma has disclosed Cash from Financing Activities across 8 years of filings, most recently posting -$272.7 million for Q1 2026.

• Cash from Financing Activities for Q1 2026 came in at -$272.7 million, up 71.03% year-over-year; the trailing twelve-month figure through Mar 2026 was -$517.3 million (down 40.52% YoY), and the FY2025 annual result was -$1.2 billion, down 428.39% from the prior year.
• Cash from Financing Activities came in at -$272.7 million for Q1 2026 at Royalty Pharma, up from -$299.6 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $1.2 billion in Q2 2024 to a low of -$1.4 billion in Q3 2023.
• The 5-year median for Cash from Financing Activities is -$258.0 million (2024), against an average of -$246.5 million.
• Across the five-year window, Cash from Financing Activities sank 490.86% in 2023 and surged 433.32% in 2024, its largest moves.
• Royalty Pharma's Cash from Financing Activities stood at -$265.6 million in 2022, then grew by 12.67% to -$231.9 million in 2023, then fell by 11.24% to -$258.0 million in 2024, then dropped by 16.14% to -$299.6 million in 2025, then grew by 8.99% to -$272.7 million in 2026.
• The last three Cash from Financing Activities figures came in at -$272.7 million (Q1 2026), -$299.6 million (Q4 2025), and $562.7 million (Q3 2025), per Business Quant data.